



OPEN

Col1 α 2-Cre-mediated recombination occurs in various cell types due to Cre expression in epiblasts

Yuzuru Matsumoto¹, Shinya Ikeda^{1,2}, Takeshi Kimura^{1,3}, Koh Ono¹ & Noboru Ashida^{1,4}✉

The Cre-LoxP system has been commonly used for cell-specific genetic manipulation. However, many Cre strains exhibit excision activity in unexpected cell types or tissues. Therefore, it is important to identify the cell types in which recombination takes place. Fibroblasts are a cell type that is inadequately defined due to a lack of specific markers to detect the entire cell lineage. Here, we investigated the Cre recombination induced by Col1 α 2-iCre, one of the most common fibroblast-mesenchymal Cre driver lines, by using a double-fluorescent Cre reporter line in which GFP is expressed when recombination occurs. Our results indicated that Col1 α 2-iCre activity was more extensive across cell types than previously reported: Col1 α 2-iCre-mediated recombination was found in not only cells of mesenchymal origin but also those of other lineages, including haematopoietic cells, myocardial cells, lung and intestinal epithelial cells, and neural cells. In addition, study of embryos revealed that recombination by Col1 α 2-iCre was observed in the early developmental stage before gastrulation in epiblasts, which would account for the recombination across various cell types in adult mice. These results offer more insights into the activity of Col1 α 2-iCre and suggest that experimental results obtained using Col1 α 2-iCre should be carefully interpreted.

The Cre-LoxP system has been a commonly used method for conditional genetic manipulations. However, it has been noted that the majority of Cre strains exhibit some degree of unintended recombination¹. Since the distribution and intensity of Cre recombinase activity have impacts on the interpretation of experiments, investigators must consider how such unintended recombination might influence their results².

Fibroblasts are found in connective tissue throughout the body and play an important role not only in wound healing but also in development, homeostasis, ageing and disease³. The majority of fibroblasts derives from the precursors of paraxial mesoderm and lateral plate mesoderm, whereas multiple cell lineages converge to form fibroblasts, for example cardiac fibroblasts are generated from epicardial and endocardial epithelial cells through epithelial-to-mesenchymal transition (EMT) and endothelial-to-mesenchymal transition (EndMT) respectively⁴. So, they are recognized as one of the most difficult cell types to identify with only one specific marker, and characterized by their morphology and the absence of leucocyte, epithelial and vascular lineage markers⁵. Although many papers have used a variety of Cre-LoxP systems to target fibroblasts, some of them have been reported to express Cre recombinase in not only fibroblasts but also other extracellular-matrix-producing cells and even in immune cells, epithelial cells, and neurons⁶. The collagen gene is commonly expressed by fibroblasts, and the alpha-2 subunit of the fibril-forming type I collagen (Col1 α 2) has been used as a marker of fibroblasts. A previous report indicated that Cre recombinase was expressed predominantly in cells of mesenchymal origin in noninducible Col1 α 2-Cre strain *Col1 α 2-iCre*⁷. However, another paper showed recombination by Col1 α 2-iCre was observed in cells other than those of mesenchymal origin⁸. We designed this study to solve this inconsistency.

In the report introducing Col1 α 2-iCre, Rosa26R-lacZ was used as a reporter line and β -galactosidase activity of Col1 α 2-iCre/Rosa26R-lacZ mice was restricted in the dermis, fibrous connective tissues surrounding internal organs, mesenchymal cells of blood vessel walls and microglial cells in brain⁷. Although Rosa26R-lacZ line has been often used, detection of β -galactosidase enzymatic activity depends on condition of protein, so that over- or underfixation can result in the underrepresentation of Cre recombinase activity. Indeed, several reports have

¹Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. ²Present address: Department of Pharmacology, Shiga University of Medical Science, Shiga, Japan. ³Present address: Hirakata Kohsai Hospital, Osaka, Japan. ⁴Present address: College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan. ✉email: nashida@fc.ritsumeik.ac.jp

suggested that Rosa26R-lacZ indicator line is less sensitive than some fluorescent indicator lines⁹. In this study, we examined the Cre recombination by Col1 α 2-iCre, with a double-fluorescent Cre reporter line⁹.

Results

Reporter line for detection of Col1 α 2-iCre characterization

To evaluate the activity of Col1 α 2-iCre, it was needed to choose the most suitable reporter line. Most Cre reporter lines, in which a marker gene (e.g. lacZ, GFP, CFP, or YFP) is expressed, can label only recombined cells. However, it is desirable to label not only recombined cells but also non-recombined cells for precise evaluation. A dual fluorescent indicator line *Rosa26R-mTmG*, in which mT/mG system expresses membrane-targeted tdTomato (“mT”) prior to Cre excision and membrane-targeted EGFP (“mG”) following Cre excision, enables us to distinguish between recombined and non-recombined cells at single-cell resolution⁹. Therefore, Col1 α 2-iCre mice were bred with Rosa26R-mTmG mice to make Col1 α 2-iCre/mTmG mice.

Recombination by Col1 α 2-iCre was observed in the dermis and epidermis

First, we examined the skin of Col1 α 2-iCre/mTmG mice. Immunofluorescence analysis showed that most fibroblasts (Vimentin +) in the dermis expressed GFP (Fig. 1a), consistent with a previous report⁷. However, another report suggested that recombination by Col1 α 2-iCre was also observed in the epidermis⁸. We found GFP-positive cells in the epidermis and hair follicles (Fig. 1b). This result indicated extensive Cre activity in cells other than those of mesenchymal origin.

Recombination by Col1 α 2-iCre was observed in haematopoietic cells

Next, we investigated recombination in the haematopoietic cells of Col1 α 2-iCre/mTmG mice because gene manipulation by Col1 α 2-iCre was reported to also occur in circulating lymphocytes and neutrophil granulocytes⁸. A flow cytometric analysis of peripheral blood showed that there was a GFP-positive population in neutrophils (22.5 \pm 5.2%), monocytes (25.4 \pm 3.5%), T cells (37.0 \pm 3.6%), and B cells (28.9 \pm 2.5%) (Fig. 2a–c, Supplementary Table S1). Since Col1 α 2-iCre-mediated recombination was observed in both myeloid and lymphoid cells, we evaluated the proportion of GFP-positive bone marrow cells. Flow cytometric analysis revealed that GFP-positive cells were observed in long-term haematopoietic stem cells (LT-HSCs; Lineage-, c-Kit+, Sca-1+, CD150+, CD48-) (24.9 \pm 5.3%), which are the most immature cells in the bone marrow (Fig. 2d,e and Supplementary Fig. S1a, Supplementary Table S1)¹⁰. Additionally, there were GFP-positive populations in short-term HSCs (ST-HSCs; Lineage-, c-Kit+, Sca1+, CD150-, CD48-) (28.8 \pm 3.7%), multipotent progenitors (MPPs; Lineage-, c-Kit+, Sca1+, CD150-, CD48+) (37.9 \pm 2.6%), downstream myeloid lineages, such as common myeloid progenitors (CMPs; Lineage-, c-Kit+, Sca-1-, CD34+, CD16/32-) (27.1 \pm 2.0%), granulocyte macrophage progenitors (GMPs; Lineage-, Sca-1-, c-Kit+, CD34+, CD16/32+, CD115-) (28.0 \pm 1.7%), monocyte-macrophage dendritic cell progenitors (MDPs; Lineage-, Sca-1-, c-Kit+, CD34+, CD16/32+, CD115+) (26.7 \pm 1.9%), and megakaryocyte-erythrocyte progenitors (MEPs; Lineage-, Sca-1-, c-Kit+, CD34-, CD16/32-) (25.9 \pm 3.1%)¹¹, and the lymphoid lineages, including common lymphoid progenitors (CLPs; Lineage-, Sca-1 low, c-Kit low, CD135+, CD127+) (33.6 \pm 4.5%), innate lymphoid cells (ILCs; Lineage-, Sca-1+, c-Kit-) (35.2 \pm 0.9%)¹². To confirm recombination in HSCs, we transplanted bone marrow cells from Col1 α 2-iCre/mTmG mice into wild-type recipients (Supplementary Fig. S1b) and analysed peripheral blood cells from the recipients 4 weeks later.




Figure 1. Recombination by Col1 α 2-iCre in the dermis and epidermis. (a) Immunostaining of dermis for vimentin (n = 3). Arrowheads indicate examples of both vimentin- and GFP-positive cells. Scale bar: 30 μ m. (b) Immunofluorescence image including epidermis (n = 3). Scale bar: 50 μ m.




Figure 2. Recombination by Col1a2-iCre in haematopoietic cells. (a) Flow cytometry of the peripheral blood cells from Col1a2-iCre/mTmG mice. (b) GFP expression in each cell type in the peripheral blood. (c) Summary of GFP expression in each cell type in the peripheral blood (n = 4). (d) The representative gating schema of bone marrow of Col1a2-iCre/mTmG mice. *LT-HSC* long-term haematopoietic stem cell, *ST-HSC* short-term haematopoietic stem cell, *MPP* multipotent progenitor, *CMP* common myeloid progenitor, *GMP* granulocyte macrophage progenitor, monocyte-macrophage dendritic cell progenitor, *MEP* megakaryocyte-erythrocyte progenitors, *CLP* common lymphoid progenitor, *ILC* innate lymphoid cell. (e) Summary of GFP expression in the bone marrow (n = 3).

There were GFP-positive cells among neutrophils ($39.4 \pm 0.5\%$), monocytes ($39.4 \pm 0.5\%$), T cells ($26.5 \pm 3.8\%$), and B cells ($47.6 \pm 3.2\%$) (Supplementary Fig. S1c), and this result verified that Col1a2-iCre recombination took place in HSCs.

Cre-mediated recombination was observed in the hearts of Col1a2-iCre/mTmG mice

Col1a2 has been commonly used as a marker of cardiac fibroblasts^{12,13}. However, the cardiac cell types that recombination by Col1a2-iCre takes place in have not been fully elucidated. We evaluated Cre-mediated recombination in the hearts of Col1a2-iCre/mTmG mice by immunohistochemistry and flow cytometric analysis. Histological staining showed that there were many fibroblasts (Vimentin⁺)¹⁴ positive for GFP (Fig. 3a), similar to vascular smooth muscle cells (α SMA⁺) (Fig. 3b), which was consistent with a previous study⁷. Surprisingly, GFP-positive cardiomyocytes (identified by morphology), endothelial cells (Isolectin B4⁺)¹⁵ and tissue macrophages (CD68⁺)¹⁶ were found in the hearts of Col1a2-iCre/mTmG mice (Fig. 3c–e). We further measured the percentage of GFP-positive nonmyocytes with flow cytometry. While $72.4 \pm 4.5\%$ of fibroblasts (CD45⁻, CD31⁻, PDGFR α ⁺) were positive for GFP, $22.6 \pm 7.1\%$ of endothelial cells (CD45⁻, CD31⁺), $26.8 \pm 4.1\%$ of tissue macrophages (CD45⁺, CD11b⁺, CD64⁺, Ly6C low), $32.1 \pm 4.2\%$ of T cells (CD45⁺, CD11b⁻, CD3 ϵ ⁺), and $25.2 \pm 1.6\%$ of B cells (CD45⁺, CD11b⁻, B220⁺) were also GFP-positive (Fig. 3f, Supplementary Table S1).

Col1a2-iCre-mediated recombination was widespread in various organs

Considering the results above, Col1a2-iCre-mediated recombination was observed in not only cells of the fibroblast-mesenchymal lineage but also cells of other lineages, such as haematopoietic cells in bone marrow, cardiomyocytes, endothelial cells and immune cells in the heart. We further investigated Col1a2-iCre-mediated recombination in other organs. Histological analysis revealed that GFP-positive cells were observed in myocytes in skeletal muscles, tubular epithelial cells in the kidney, hepatocytes in the liver, pneumocytes in the lung, glandular epithelium in the intestine, and neural cells in the cerebral cortex and retina (Supplementary Fig. S2a–l).

Col1a2-iCre-mediated recombination occurred in epiblasts

According to previous studies, the first expression of the endogenous collagen I gene was reported to start at embryonic day (E) 8.5^{17,18}, which is the postgastrulation stage. However, it cannot explain the extent of GFP-positive cell types in Col1a2-iCre/mTmG mice. Although the majority of fibroblasts originate from paraxial mesoderm and lateral plate mesoderm⁴, epidermal cells and neural cells are derived from ectoderm; hepatocytes, gut and lung epithelium are from endoderm; cardiomyocytes and intraembryonic haematopoietic cells also come from intraembryonic mesoderm, but they are transcriptomically different from mesenchyme (Supplementary Fig. S3a)¹⁹. Therefore, our results implicated that Col1a2-iCre expression had started earlier than the three germ layers arise. So, we investigated the timing of endogenous Col1a2 gene expression during mouse embryogenesis by analysing public single-cell RNA sequencing (scRNA-seq) datasets^{19,20}. First, we reanalyzed the scRNA-seq dataset of E4.5, E5.25, E5.5, E6.25 and E6.5 murine embryos²⁰. Although the Col1a2 gene was not detected in blastocytes at E4.5, Col1a2 mRNA was expressed in the epiblast (EPI) cluster from E5.25 to E6.5 and less in the extraembryonic ectoderm (ExE) and visceral endoderm (VE) cluster (Fig. 4a). Next, we used scRNA-seq datasets spanning from E6.75 to E13.5¹⁹. They showed that Col1a2 mRNA was expressed predominantly in the allantois, the amniochorionic mesoderm, the splanchnic mesoderm (except for cardiomyocytes), mesenchymal stromal cells, chondrocytes and osteoblast precursors (Supplementary Fig. S3b–f). To validate Col1a2-iCre-mediated recombination before gastrulation, we examined Col1a2-iCre/mTmG mouse embryos at E6.5 by histological analysis and revealed that GFP expression was observed in more than half of the epiblasts and nascent mesoderm, partly in the visceral endoderm, and rarely in extraembryonic lesions (Fig. 4b). This result was fairly consistent with our scRNA-seq analysis, and we concluded that recombination by Col1a2-iCre occurred in epiblasts. Finally, we examined embryonic bodies at E9.5, E13.5 and E17.5 to validate the recombination across cell lineages. GFP-positive cells were found in not only cells of the fibroblast-mesenchymal lineage but also cells of the myocardium, vessel wall, lung, liver, gut, urinary system, nerve system and genital organs at each time point (Supplementary Fig. S4a–c). This widespread recombination was a result of recombination events in epiblasts.

Col1a2-CreER recombination in skin and heart.


Considering the popularity of drug-inducible Cre strain, we analyzed an inducible Col1a2-Cre line (Col1a2-CreER)²¹. GFP-positive population was detected in dermal connective tissue, but GFP-positive cells were not detected in epidermis of Col1a2-CreER/mTmG mice (Supplementary Fig. S5a). In the heart of Col1a2-CreER/mTmG mice, GFP-positive cells were found only in fibroblasts (Fig. 5a, Supplementary Fig. S5c) and VSMCs (Fig. 5b), not in cardiomyocytes, endothelial cells and leukocytes (Supplementary Fig. S5b,c). However, comparing to Col1a2-iCre/mTmG hearts, Col1a2-CreER/mTmG hearts showed a significantly reduced recombination efficiency in fibroblasts ($39.0 \pm 2.0\%$ versus $72.4 \pm 4.5\%$; $P < 0.001$), as well as endothelial cells ($0.0 \pm 0.0\%$ versus $22.6 \pm 7.1\%$; $P = 0.04$) and leukocytes ($0.0 \pm 0.0\%$ versus $22.6 \pm 7.1\%$; $P = 0.01$) (Fig. 5c, Supplementary Table S1).

Discussion


The Cre-LoxP system is widely used for conditional gene targeting. However, many Cre strains, including fibroblast-targeting Cre, have been reported to exhibit some degree of unexpected recombination¹. In the present study, a double-fluorescent Cre reporter line Rosa26R-mTmG mice, instead of Rosa26R-lacZ mice, demonstrated Col1a2-iCre-mediated recombination in cells other than those of mesenchymal origin. Next, we confirmed that Col1a2-iCre-mediated recombination took place in epiblasts before gastrulation.

First, histological and flow cytometric analyses of adult and prenatal Col1a2-iCre/mTmG mice revealed that Cre-mediated recombination was present in not only cells of mesenchymal origin but also cells of other


a Cardiac fibroblast




b Vascular smooth muscle cell (VSMC)



c Myocardium



d Endothelial cell



e Macrophage





Figure 3. Recombination by Col1a2-iCre across cell types in the heart. (a) Immunofluorescence image of cardiac fibroblasts (n = 5). The arrowheads indicate examples of both vimentin- and GFP-positive cells. Scale bar: 50 μm. (b) Immunofluorescence image of vascular smooth muscle cells (VSMCs) (n = 5). Scale bar: 50 μm. (c) GFP-positive myocardial cells. The upper image is a whole image, and the lower image is a magnified image (n = 5). (d) GFP-positive endothelial cell (arrowheads) (n = 5). Scale bar: 50 μm. (e) GFP-positive macrophage (arrowheads) (n = 5). Scale bar: 30 μm. (f) The representative gating schema of nonmyocytes of Col1a2-iCre/mTmG hearts and GFP expression in each cell type.





Figure 4. *Col1a2*-iCre recombination occurred in epiblasts. **(a)** UMAP visualizations of all the cells from E5.25, E5.5, E6.25 and E6.5 together ($n = 1724$) categorized by embryonic day (top left) and cell type (top right). The lower panel is a violin plot of the *Col1a2* gene expression. **(b)** Left: illustration of an E6.5 embryo. Right: HE staining and immunofluorescence images of E6.5 embryos ($n = 3$). The signal intensity of Tomato in epiblasts was much weaker than that in maternal cells. *EPI* epiblast, *VE* visceral endoderm, *ExE* extraembryonic ectoderm, *Ex* extraembryonic, *E* embryonic.

lineages, including but also cells of other lineages, such as hematopoietic, myocardial, lung, and intestinal epithelial, and neural cells. However, a previous paper, in which Cre recombinase activity of *Col1a2*-iCre mice was examined by using *Rosa26R*-lacZ indicator line, reported that β -galactosidase expression was restricted in cells of mesenchymal origin⁷. This inconsistency was attributed to reporter line: *Rosa26R*-mTmG line might be more sensitive than *Rosa26R*-lacZ line and the mTmG system allowed us to identify recombined cells thanks to dual membrane-targeted fluorescence.

Second, *Col1a2*-iCre-mediated recombination was observed in epiblasts before gastrulation. Many genes are transiently expressed in the germ line or at various stages of development² and Cre expression coinciding with such transient expression, even if it is not biologically important, could generate unexpected recombination. In line with a previous report, reanalysis of scRNA-seq datasets and histological analysis during early mouse




a Cardiac fibroblast**b Vascular smooth muscle cell (VSMC)****c**

Figure 5. Cre recombination in skin and heart of Col1a2-CreER/mTmG mice. **(a)** Immunofluorescence image of cardiac fibroblasts. Arrowheads indicate examples of both vimentin and GFP-positive cells ($n = 3$). Scale bar: 50 μm . **(b)** Immunofluorescence image of vascular smooth muscle cells (VSMCs) ($n = 3$). Scale bar: 50 μm . **(c)** Summary of GFP expression in Col1a2-iCre/mTmG and Col1a2-CreER/mTmG hearts (fibroblast and endothelial cell of Col1a2-iCre/mTmG heart: $n = 5$, leukocyte of Col1a2-iCre/mTmG heart: $n = 8$, fibroblast, endothelial cell and leukocyte of Col1a2-CreER/mTmG: $n = 3$). Statistical significance was analyzed by Student's t test (fibroblast) and by Wilcoxon rank sum test (endothelial cell and leukocyte).

embryogenesis revealed that the expression of the endogenous Col1a2 gene in epiblasts before gastrulation led to recombination by Col1a2-iCre in epiblasts. Since epiblasts give rise to almost all of the foetal tissues and the extraembryonic mesoderm²², these results explained the extensive Cre recombinase activity in various cell types of Col1a2-iCre mice. It is possible that an improved Cre (iCre)²³ might increase recombination events by Col1a2-iCre, but unexpected Cre recombination can occur in any Cre strain due to Cre expression in undifferentiated cells during the early developmental stage.

Many Cre strains have been used to describe fibroblast behavior. Since fibroblasts originate from multiple cell lineage, genes expressed in fibroblasts might overlap with those in other cell types. Therefore, Cre strains targeting fibroblasts, especially noninducible strains, exhibit unexpected recombinase activity in other cell lineages. Although Col1a2-iCre strain has an extensive recombinase activity, other “classical” fibroblast Cre strains such as *Col1a1*-, *Pdgfra*-, *Tcf21*-, *Ddr2*-Cre also exhibit some degree of unintended recombination in other cell types including intestinal, endothelial, neural cells⁶. There are two ways to improve specificity and accuracy. One is to generate more fibroblast-specific Cre strains, such as ITGA11-Cre, which was reported recently²⁴. The other way is to use inducible Cre strains such as the tamoxifen-inducible Cre system or Tet-on/off system. We also analyzed the skin and heart of Col1a2-CreER/mTmG mouse to show relatively specific recombination in cardiac fibroblasts and VSMCs (Fig. 5a,b, Supplementary Fig. S5b,c). However, Col1a2-CreER/mTmG mice had a lower recombination efficiency in cardiac fibroblasts comparing to Col1a2-iCre/mTmG mice (Fig. 5c). Indeed, previous reports indicated that when using an inducible Cre line, the population of recombined cells is much smaller than expected depending on the target gene or cell type of interest^{25,26}. Additionally, the inducible

Cre system has several limitations: one is that the tissue distribution of exogenous inducers and their active metabolites depends on the administration protocols and target organs²⁶; the second is the toxicity of the inducers. For example, high doses of tamoxifen may cause focal cardiac fibrosis in combination with MerCreMer^{27,28}. Another is the direct toxicity of temporal Cre expression itself. According to a previous paper, activation of Cre/ERT2 by the administration of tamoxifen caused thymus atrophy, severe anaemia, and abnormal chromosomal rearrangement in haematopoietic cells²⁸. Therefore, researchers who plan to use an inducible Cre system should check the recombination efficiency by using a Cre indicator line, like the mTmG system, and evaluate effects of the inducer itself.

Considering the results in the current study, inadvertent and widespread recombination events in various cell types could impact the interpretation of experimental results, and we must be cautious of the results when using Cre-LoxP systems. This study also illustrated a pipeline for the assessment of Cre-mediated recombination events and extensive recombinase activity of Col1a2-iCre. We emphasize the importance of a thorough characterization of the Cre strain, and investigators should take the unexpected Cre recombination events into consideration when they design experimental strategies.

Methods

Animals

All animal experiments were performed in accordance with the institutional guidelines of the Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University (Kyoto, Japan), and all experimental protocols were approved by the same institute. Our study was reported in accordance with ARRIVE guidelines.

The noninducible Cre driver line *Col1a2-iCre* is Tg(Col1a2-cre)²³Angl, previously reported by Florin et al.⁷, in which the cDNA encoding an improved Cre recombinase (iCre) was fused to the start codon of the *Col1a2* gene. The inducible strains *Col1a2-CreER*, a transgenic line, Tg(Col1a2-cre/ERT), and ALPP7Cpd and the Cre reporter line (*Rosa26R*)-*mTmG* (B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato, -EGFP)^{Luo/J}) were purchased from the Jackson Laboratory (#029567 and #007676 respectively).

For experiments of adult *Col1a2-iCre/mTmG* and *Col1a2-CreER/mTmG* mice, we used 8–10 weeks old mice. For the inducible Cre line, the induction of Cre recombination was started from 7–8 weeks of age by administration of tamoxifen (75 mg/kg body weight) via intraperitoneal injection once every 24 h for a total of 5 consecutive days and samples were collected after a 7-day waiting period. To obtain *Col1a2-iCre/mTmG* embryos, three adult *mTmG* floxed females were housed together with a fertile *Col1a2-iCre* male overnight and separated the following morning. The vaginal plug was observed, and real-time ultrasound imaging at E5.5 was conducted as previously described²⁹ to confirm the pregnancy. For euthanasia, sedation was performed by intraperitoneal administration of a mixture of medetomidine (0.3 mg/kg body weight), midazolam (4 mg/kg body weight) and butorphanol (5 mg/kg body weight).

Immunostaining

Adult mice were perfused with PBS and 4% paraformaldehyde (PFA). The samples were fixed for 6–24 h in 4% PFA and dehydrated 12 h in sucrose (10% and 30% sucrose in PBS sequentially) before embedding in OCT compound (Sakura Finetek Japan, #45833). *Col1a2-iCre/mTmG* embryos were collected at E6.5, E9.5, E13.5, and E17.5. Embryos were dissected from the decidua and washed twice with ice-cold PBS. They were fixed for 3 h in 4% PFA and dehydrated in sucrose (10%, 20% and 30% sucrose in PBS sequentially) before embedding in OCT compound. Sections (8 µm) were obtained using a cryostat (Leica Biosystems). For the observation of mT and mG only, samples were washed three times with PBS and mounted with VECTASHIELD HardSet Antifade Mounting Medium with DAPI (Vector Laboratories, #H-1500). For the immunofluorescence study, sections were rinsed with PBS and then incubated in blocking buffer (PBS containing 0.1% Tween 20, 1% bovine serum albumin and 10% normal donkey serum (Jackson ImmunoResearch, #017-000-121) for 1 h at room temperature. Next, they were stained with primary antibodies diluted in blocking buffer overnight at 4 °C. The concentrations of the primary antibodies are provided in Supplementary Table S2. On the following day, the sections were washed three times in ice-cold PBS containing 0.1% Tween20 for 5 min each and incubated with secondary antibodies against the appropriate species at a 1:500 dilution for 1 h at room temperature. They were washed three times in ice-cold PBS for 5 min each. Finally, the samples were mounted with the above-referenced mounting medium. Immunofluorescence studies of cardiac endothelial cells were conducted with DyLight[™] 649-conjugated anti-Griffonia simplicifolia isolectin B4 (1:100) (Vector Laboratories, # DL-1208-.5) according to the manufacturer's instructions.

Fluorescence images were acquired by using BZ-X810 (Keyence) or SP8 Falcon (Leica Biosystems).

Flow cytometric analysis

Blood samples were collected from the jugular vein using a heparin-containing syringe. Red blood cell lysis was performed with RBC lysis buffer (BioLegend). Then, the samples were washed with FACS buffer (HBSS with 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2% FBS, and 2 mM ethylenediaminetetraacetic acid (EDTA)) and resuspended. The cells were blocked with TruStain FcX Plus (BioLegend, #156603) for 5 min at 4 °C.

To prepare a single-cell suspension of noncardiomyocytes, we adopted a previously reported dissociation protocol³⁰. Hearts were perfused with ice-cold PBS and removed. The ventricles were finely minced and digested in Hank's balanced salt solution (HBSS) with collagenase 2 (500 U/ml) (Worthington Biochemical, #LS004176) for 30 min at 37 °C and then incubated in HBSS with collagenase/dispase (1 mg/mL) (Merck, #11097113001) for 20 min at 37 °C. To deactivate the enzymes, the samples were washed with ice-cold HBSS and passed through a

40 µm cell strainer (Corning, #352340). After red blood cell lysis, the cardiac samples were washed with FACS buffer and resuspended and then blocked with TruStain FcX Plus for 5 min at 4 °C.

Bone marrow cells were flushed from femurs and tibias with RPMI supplemented with 25 mM HEPES and 10% FBS and filtered through a 40 µm cell strainer (Falcon, #352340). After the red blood cells were lysed, the samples were washed with 2% FBS-containing HBSS buffer and resuspended.

The cells were stained with conjugated primary antibodies (see Supplementary Table S1) and then analysed by flow cytometry with FACSARIA™ IIu (BD Biosciences) and FACSDiva software (BD Biosciences) or FlowJo software (Tree Star).

Bone marrow transplantation

Bone marrow cells were collected from Col1α2-iCre/mTmG mice and injected 5.0×10^6 cells into wild-type recipient mice that received a total radiation dose of 12 Gy in two 6 Gy fractions separated by a 3-h interval (Supplementary Fig. S2b).

scRNA-seq data

Transcriptional data at E4.5, E5.25, E5.5, E6.25 and E6.5 were downloaded in raw-count forms from the Gene Expression Omnibus of the National Center for Biotechnology Information GSE109071 dataset. The data were processed with the R (4.1.3) package Seurat version 4 by weighted-nearest neighbour analysis³¹.

The other datasets spanning E6.75 to E13.5 were obtained in processed forms from <http://tome.gs.washington.edu/>²⁰. These objects were analysed with R (4.1.3) package Seurat version 4.

Statistics

All results are presented as the mean ± SEM. Differences between two groups were compared by Student's t test as a parametric comparison test or by Wilcoxon rank sum test as a nonparametric comparison test. The analysis and plots were generated using the R (4.1.3) package ggplot2 version 3.

Data availability

All data generated or analyzed during this study are included in this published article and its supplementary information file.

Received: 17 October 2023; Accepted: 14 December 2023

Published online: 18 December 2023

References

- Heffner, C. S. *et al.* Supporting conditional mouse mutagenesis with a comprehensive cre characterization resource. *Nat. Commun.* <https://doi.org/10.1038/ncomms2186> (2012).
- Song, A. J. & Palmiter, R. D. Detecting and avoiding problems when using the Cre-lox system. *Trends Genet.* **34**, 333–340 (2018).
- Gauthier, V. *et al.* Fibroblast heterogeneity: Keystone of tissue homeostasis and pathology in inflammation and ageing. *Front. Immunol.* <https://doi.org/10.3389/fimmu.2023.1137659> (2023).
- Plikus, M. V. *et al.* Fibroblasts: Origins, definitions, and functions in health and disease. *Cell* **184**, 3852–3872 (2021).
- Denu, R. A. *et al.* Fibroblasts and mesenchymal stromal/stem cells are phenotypically indistinguishable. *Acta Haematol.* **136**, 85–97 (2016).
- Swonger, J. M., Liu, J. S., Ivey, M. J. & Tallquist, M. D. Genetic tools for identifying and manipulating fibroblasts in the mouse. *Differentiation* **92**(3), 66–83. <https://doi.org/10.1016/j.diff.2016.05.009> (2016).
- Florin, L. *et al.* Cre recombinase-mediated gene targeting of mesenchymal cells. *Genesis* **38**, 139–144 (2004).
- Florin, L. *et al.* Delayed wound healing and epidermal hyperproliferation in mice lacking JunB in the skin. *J. Invest. Dermatol.* **126**, 902–911 (2006).
- Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, N. & Luo, L. A global double-fluorescent cre reporter mouse. *Genesis* **45**, 593–605 (2007).
- Kiel, M. J. *et al.* SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. *Cell* **121**, 1109–1121 (2005).
- Hulsmans, M. *et al.* Cardiac macrophages promote diastolic dysfunction. *J. Exp. Med.* **215**, 423–440 (2018).
- Lal, H. *et al.* Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart. *Circulation* **130**, 419–430 (2014).
- Lu, W., Meng, Z., Hernandez, R. & Zhou, C. Fibroblast-specific IKK-β deficiency ameliorates angiotensin II-induced adverse cardiac remodeling in mice. *JCI Insight* <https://doi.org/10.1172/jci.insight.150161> (2021).
- Moore-Morris, T. *et al.* Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. *J. Clin. Invest.* **124**, 2921–2934 (2014).
- Pinto, A. R. *et al.* Revisiting cardiac cellular composition. *Circ. Res.* **118**, 400–409 (2016).
- Bizou, M. *et al.* Cardiac macrophage subsets differentially regulate lymphatic network remodeling during pressure overload. *Sci. Rep.* <https://doi.org/10.1038/s41598-021-95723-y> (2021).
- Khillan, J. S., Schmidt, A., Overbeek, P. A., De Crombrugghet, B. & Westphal, H. Developmental and tissue-specific expression directed by the α2 type I collagen promoter in transgenic mice (developmental regulation/type I collagen genes). *Proc. Natl. Acad. Sci.* **83**(3), 725–729 (1986).
- Verlag, G. F. *et al.* Coordinate patterns of expression of type I and III collagens during mouse development. *Matrix Biol.* **14**(9), 705–713 (1994).
- Qiu, C. *et al.* Systematic reconstruction of cellular trajectories across mouse embryogenesis. *Nat. Genet.* **54**, 328–341 (2022).
- Cheng, S. *et al.* Single-cell RNA-seq reveals cellular heterogeneity of pluripotency transition and X chromosome dynamics during early mouse development. *Cell Rep.* **26**(10), 2593–2607 (2019).
- Zheng, B., Zhang, Z., Black, C. M., De Crombrugghet, B. & Denton, C. P. Ligand-dependent genetic recombination in fibroblasts: A potentially powerful technique for investigating gene function in fibrosis. *Am. J. Pathol.* **160**(5), 1609–1617 (2002).
- Rivera-Pérez, J. A. & Hadjantonakis, A. K. The dynamics of morphogenesis in the early mouse embryo. *Cold Spring Harb. Perspect. Biol.* **7**(11), a015867 (2015).
- Shimshak, D. R. *et al.* Codon-improved Cre recombinase (iCre) expression in the mouse. *Genesis* **32**, 19–26 (2002).

24. Alam, J. *et al.* Generation of a novel mouse strain with fibroblast-specific expression of Cre recombinase. *Matrix Biol. Plus* **8**, 100045 (2020).
25. Turlo, K. A., Gallaher, S. D., Vora, R., Laski, F. A. & Iruela-Arispe, M. L. When Cre-mediated recombination in mice does not result in protein loss. *Genetics* **186**, 959–967 (2010).
26. Ilchuk, L. A. *et al.* Limitations of tamoxifen application for in vivo genome editing using Cre/ERT2 system. *Int. J. Mol. Sci.* **23**(22), 14077 (2022).
27. Lexow, J., Poggioli, T., Sarathchandra, P., Santini, M. P. & Rosenthal, N. Cardiac fibrosis in mice expressing an inducible myocardial-specific Cre driver. *DMM Dis. Models Mech.* **6**, 1470–1476 (2013).
28. Higashi, A. Y. *et al.* Direct hematological toxicity and illegitimate chromosomal recombination caused by the systemic activation of CreERT2. *J. Immunol.* **182**, 5633–5640 (2009).
29. Greco, A. *et al.* High frequency ultrasound for in vivo pregnancy diagnosis and staging of placental and fetal development in mice. *PLoS One* **8**(10), e77205 (2013).
30. Pinto, A. R., Chandran, A., Rosenthal, N. A. & Godwin, J. W. Isolation and analysis of single cells from the mouse heart. *J. Immunol. Methods* **393**, 74–80 (2013).
31. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587.e29 (2021).

Acknowledgements

This work was supported by JSPS KAKENHI Grant Numbers 25461497, 16H05297, 18K08068, and 21K08103.

Author contributions

Y.M. designed the overall study, performed experiments, analysed the results and wrote the manuscript; S.I. designed the study, performed experiments, and analysed the results; T.K., K.O., and N.A. supervised the study. All of the authors have read and reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-023-50053-z>.

Correspondence and requests for materials should be addressed to N.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023